State of Wisconsin Investment Board purchased a new position in shares of Agenus Inc. (NASDAQ:AGEN) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 53,000 shares of the biotechnology company’s stock, valued at approximately $207,000. State of Wisconsin Investment Board owned about 0.05% of Agenus as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in AGEN. Wells Fargo & Company MN increased its stake in shares of Agenus by 1.9% during the 1st quarter. Wells Fargo & Company MN now owns 466,799 shares of the biotechnology company’s stock worth $1,759,000 after purchasing an additional 8,921 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Agenus by 38.1% during the 1st quarter. Bank of New York Mellon Corp now owns 560,799 shares of the biotechnology company’s stock worth $2,114,000 after purchasing an additional 154,715 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Agenus by 7.8% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 97,342 shares of the biotechnology company’s stock worth $367,000 after purchasing an additional 7,050 shares during the last quarter. UBS Asset Management Americas Inc. increased its stake in shares of Agenus by 203.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 51,933 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 34,833 shares during the last quarter. Finally, Glenview Trust Co increased its stake in shares of Agenus by 32.4% during the 1st quarter. Glenview Trust Co now owns 187,408 shares of the biotechnology company’s stock worth $707,000 after purchasing an additional 45,856 shares during the last quarter. Institutional investors own 39.51% of the company’s stock.

Several research analysts have recently commented on AGEN shares. ValuEngine upgraded shares of Agenus from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Wednesday, July 5th. Jefferies Group LLC restated a “buy” rating and set a $7.00 price target on shares of Agenus in a research note on Friday, August 4th. Finally, BidaskClub lowered shares of Agenus from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. Agenus currently has an average rating of “Hold” and a consensus price target of $5.88.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/16/53000-shares-in-agenus-inc-agen-acquired-by-state-of-wisconsin-investment-board.html.

Shares of Agenus Inc. (NASDAQ AGEN) opened at 4.12 on Friday. The company’s market capitalization is $410.81 million. Agenus Inc. has a 12-month low of $3.20 and a 12-month high of $7.49. The company’s 50 day moving average is $3.86 and its 200 day moving average is $3.86.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.04. Agenus had a negative net margin of 280.96% and a negative return on equity of 37,577.49%. The company had revenue of $4.21 million for the quarter, compared to the consensus estimate of $6.66 million. During the same period last year, the company earned ($0.33) earnings per share. The firm’s revenue was down 36.1% compared to the same quarter last year. Analysts expect that Agenus Inc. will post ($1.13) earnings per share for the current fiscal year.

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Stock Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related stocks with our FREE daily email newsletter.